| Afatinib studied in …STUDIED_INderived163 of 163show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 163 trials list this drug (19 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06302621Phase 1 · recruiting Pemigatinib + Afatinib in Advanced Refractory Solid Tumors · 163 trials list this drug (19 active) | — | — | Solid Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05215548Phase 2 · recruiting Primary Tumor Resection With EGFR TKI for Stage IV NSCLC · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439136Phase 2 · active not recruiting Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) · 163 trials list this drug (19 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03785249Phase 1/Phase 2 · active not recruiting Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 · 163 trials list this drug (19 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06385483Phase 2 · active not recruiting Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) · 163 trials list this drug (19 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05070403Phase 2 · active not recruiting Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma · 163 trials list this drug (19 active) | — | — | Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07010120Phase 1/Phase 2 · active not recruiting A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma · 163 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07040956Phase 2 · completed A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. · 163 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02491099Phase 2 · recruiting A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06648096Phase 1/Phase 2 · recruiting Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) · 163 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02438722Phase 2/Phase 3 · completed S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05588609Phase 2 · terminated Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers · 163 trials list this drug (19 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01783587Phase 1 · completed Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer · 163 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02979977Phase 2 · completed Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01856478Phase 3 · completed LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy · 163 trials list this drug (19 active) | — | — | Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06494189Phase 1 · completed Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma · 163 trials list this drug (19 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06085755Phase 1/Phase 2 · recruiting Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer · 163 trials list this drug (19 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06753747Phase 1/Phase 2 · recruiting A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma · 163 trials list this drug (19 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06804850Phase 2 · withdrawn Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC · 163 trials list this drug (19 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04185883Phase 1 · active not recruiting Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) · 163 trials list this drug (19 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00716417Phase 1 · completed Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05517330Phase 2 · completed Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma · 163 trials list this drug (19 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02191891Phase 1 · completed Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05516589Phase 2 · completed Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC · 163 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02122172Phase 2 · terminated Afatinib in Advanced Refractory Urothelial Cancer · 163 trials list this drug (19 active) | — | — | Malignant Bladder Neoplasm,Malignant Ureter Neoplasm,Malignant Urethral Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05432518early Phase 1 · recruiting Pilot Trial for Treatment of Recurrent Glioblastoma · 163 trials list this drug (19 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01853826Phase 3 · completed An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834348completed A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04206787completed The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer · 163 trials list this drug (19 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02597946Phase 2 · completed Afatinib in NSCLC With HER2 Mutation · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03083678Phase 2 · completed Afatinib in Locally Advanced and Metastatic Chordoma · 163 trials list this drug (19 active) | — | — | Chordoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01649271Phase 1 · completed Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. · 163 trials list this drug (19 active) | — | — | Breast Neoplasm,Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00950742Phase 1 · completed Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. · 163 trials list this drug (19 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01214616Phase 1 · completed BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02171650Phase 1 · completed BIBW 2992 in Patients With Advanced Solid Tumors · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06759857Phase 3 · enrolling by invitation FHND9041 Versus Afatinib for Non-small Cell Lung Cancer · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04795245completed Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma · 163 trials list this drug (19 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06741982Phase 1 · recruiting A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus · 163 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01553942Phase 2 · active not recruiting Afatinib With CT and RT for EGFR-Mutant NSCLC · 163 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364609Phase 1 · completed Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04183712Phase 2 · recruiting Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA · 163 trials list this drug (19 active) | — | — | Gallbladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04750824completed Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. · 163 trials list this drug (19 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04909073unknown Observational Study of Afatinib 30 mg Daily · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04410653Phase 2 · completed Afatinib in Advanced NRG1-Rearranged Malignancies · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 163 trials list this drug (19 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01542437Phase 2 · completed Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02768337Phase 1/Phase 2 · terminated Cambridge Brain Mets Trial 1 · 163 trials list this drug (19 active) | — | — | Malignant Breast Neoplasm,Malignant Lung Neoplasm,Malignant Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 163 trials list this drug (19 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02795156Phase 2 · completed Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma,Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02183883Phase 2 · completed Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03088059Phase 2 · unknown Biomarker-based Study in R/M SCCHN · 163 trials list this drug (19 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03727724Phase 2 · completed Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02506517Phase 2 · completed A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene · 163 trials list this drug (19 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01824823Phase 2 · terminated Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence · 163 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05865132Phase 2 · unknown Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction · 163 trials list this drug (19 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03827070Phase 1 · unknown Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05818982Phase 2 · unknown To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC · 163 trials list this drug (19 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05267288Phase 2 · unknown Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02501603Phase 2 · completed Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer · 163 trials list this drug (19 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04201756Phase 2 · completed Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma · 163 trials list this drug (19 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03574402Phase 2 · unknown Phase II Umbrella Study Directed by Next Generation Sequencing · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05107193no longer available Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors) · 163 trials list this drug (19 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02716311Phase 2 · completed Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03711422Phase 1 · terminated Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC · 163 trials list this drug (19 active) | — | — | Meningeal Neoplasm,Leptomeningeal Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02451553Phase 1 · completed Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer · 163 trials list this drug (19 active) | — | — | Malignant Solid Neoplasm,Malignant Pancreatic Neoplasm,Pancreatic Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02440854completed Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03695510Phase 2 · completed Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) · 163 trials list this drug (19 active) | — | — | Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03054038Phase 1 · terminated Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01156545Phase 2 · completed BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02423525Phase 1 · completed Safety Study of Afatinib for Brain Cancer · 163 trials list this drug (19 active) | — | — | Malignant Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03239015Phase 2 · unknown Efficacy and Safety of Precision Therapy in Refractory Tumor · 163 trials list this drug (19 active) | — | — | Neoplasm,Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01415674Phase 2 · completed Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients · 163 trials list this drug (19 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05164848Phase 1 · unknown JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02629523Phase 2 · completed Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA · 163 trials list this drug (19 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04880811Phase 2 · unknown Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification · 163 trials list this drug (19 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01427478Phase 3 · completed Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck · 163 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04814056Phase 4 · unknown To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02747953Phase 2 · completed Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02372006Phase 1/Phase 2 · completed Trial of Afatinib in Pediatric Tumours · 163 trials list this drug (19 active) | — | — | Primitive Neuroectodermal Tumor,Rhabdomyosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02285361completed GIOTRIF rPMS in Korean Patients With NSCLC · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03157089Phase 2 · completed Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03370770completed Afatinib Osimertinib Sequencing NIS · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04640870completed The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02780687Phase 2 · completed Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy · 163 trials list this drug (19 active) | — | — | Urinary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04575415unknown Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04533321Phase 2 · unknown A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma · 163 trials list this drug (19 active) | — | — | Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01746251Phase 2 · unknown Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04158947Phase 2 · unknown A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone · 163 trials list this drug (19 active) | — | — | Brain Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02541903Phase 2 · terminated Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma · 163 trials list this drug (19 active) | — | — | Penile Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01466660Phase 2 · completed LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung · 163 trials list this drug (19 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02514174Phase 4 · completed Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02047903completed GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02115048Phase 2 · terminated Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone · 163 trials list this drug (19 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04132102Phase 4 · unknown To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation · 163 trials list this drug (19 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01679405Phase 1 · terminated BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01953913Phase 3 · completed Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01125566Phase 3 · completed LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment · 163 trials list this drug (19 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03652233Phase 1 · withdrawn Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck · 163 trials list this drug (19 active) | — | — | Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03940976Phase 2 · unknown Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01) · 163 trials list this drug (19 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02271906Phase 2 · terminated The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting · 163 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02595840Phase 2 · terminated Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE) · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02131155Phase 3 · terminated LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy · 163 trials list this drug (19 active) | — | — | Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00977431Phase 1 · completed Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform · 163 trials list this drug (19 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01523587Phase 3 · completed LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02353936Phase 2 · unknown A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus · 163 trials list this drug (19 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03810872Phase 2 · unknown An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01415011Phase 2 · completed Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02208843Phase 4 · completed Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01121393Phase 3 · completed BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) · 163 trials list this drug (19 active) | — | — | Adenocarcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01931306approved for marketing Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC) · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02131259completed Long-term Observation PMS for Afatinib · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02450656Phase 1/Phase 2 · unknown Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer · 163 trials list this drug (19 active) | — | — | Digestive System Neoplasm,Pancreatic Neoplasm,Colorectal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01732640Phase 1/Phase 2 · terminated A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. · 163 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01538381Phase 2 · completed Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck · 163 trials list this drug (19 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00949650Phase 3 · completed BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation · 163 trials list this drug (19 active) | — | — | Adenocarcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03486509Phase 2 · unknown Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma · 163 trials list this drug (19 active) | — | — | Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01074177NA · completed Understanding Mechanisms of Acquired Resistance to BIBW2992 · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01345682Phase 3 · completed LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy · 163 trials list this drug (19 active) | — | — | Head and Neck Neoplasm,Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02488694Phase 2 · terminated Maintaining ERBB Blockade in EGFR-mutated Lung Cancer · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01345669Phase 3 · terminated LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy · 163 trials list this drug (19 active) | — | — | Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02695290Phase 4 · terminated Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02876081Phase 2 · withdrawn Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex · 163 trials list this drug (19 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00727506Phase 2 · completed BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma · 163 trials list this drug (19 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01728818Phase 2 · unknown Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours · 163 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020577Phase 1 · completed Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01085136Phase 3 · completed LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02044380Phase 3 · completed Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02274012Phase 2 · withdrawn Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment · 163 trials list this drug (19 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01649284approved for marketing Afatinib Expanded Access Program · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01209650approved for marketing LUX Lung Special Access Scheme Australia Named Patient Use (NPU) · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01814553Phase 3 · completed ADAM-Afatinib Diarrhea Assessment and Management · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00525148Phase 2 · completed LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00514943Phase 2 · completed BIBW 2992 (Afatinib) in Head & Neck Cancer · 163 trials list this drug (19 active) | — | — | Head and Neck Neoplasm,Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00656136Phase 3 · completed BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01251653completed A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02511847Phase 2 · unknown Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib · 163 trials list this drug (19 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00809133Phase 1 · completed Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02470065Phase 2 · suspended Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02625168Phase 2 · completed Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC · 163 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00993499Phase 1 · completed Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01090011Phase 1 · completed Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01441596Phase 2 · completed Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases · 163 trials list this drug (19 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00998296Phase 1 · completed Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours. · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02171663Phase 1 · completed Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00706628Phase 2 · completed A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer · 163 trials list this drug (19 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00796549Phase 2 · completed BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01152437Phase 2 · completed A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer · 163 trials list this drug (19 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02171637Phase 1 · completed Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02171676Phase 1 · completed BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02171702Phase 1 · completed Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02171728Phase 1 · completed Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02171741Phase 1 · completed Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00431067Phase 2 · completed Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy · 163 trials list this drug (19 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00730925Phase 2 · completed Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01594177Phase 2 · completed Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy · 163 trials list this drug (19 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00425854Phase 2 · completed An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer · 163 trials list this drug (19 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00826267Phase 2 · completed 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab · 163 trials list this drug (19 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01003899Phase 2 · completed A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR] · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00708214Phase 2 · completed BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer · 163 trials list this drug (19 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00875433Phase 2 · completed Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01836341Phase 1 · withdrawn Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation · 163 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00730821Phase 1 · completed Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors · 163 trials list this drug (19 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |